The race to find medical treatments for Covid-19—and future pandemics—is on, driving renewed investments by the healthcare and pharmaceutical industries in Real-World Data (RWD) and Real-World Evidence (RWE). A new report on AI and the real-world studies industry, from Deep Pharma Intelligence (DPI), Evomics Medical and The Yuan (an online forum focused on AI in healthcare, for which I am a contributor), provides fresh insights into this rapidly evolving patient-centric approach to increasing R&D efficiency, accelerating the introduction of new drugs, and improving health outcomes. Full Story:
Comments are closed.